Successful Treatment of Trichosporon asahii Fungemia with Isavuconazole in a Patient with Prominent Renal Dysfunction and Intestinal Absorption Disorder

Abstract

Trichosporon asahii fungemia often occurs in immunosuppressed patients and has a mortality rate of up to 50%. T. asahii is the most common cause of Trichosporon fungemia. T. asahii is typically treated with azole class antifungals, especially voriconazole (VRCZ). In contrast, intravenous VRCZ contains sulfobutylether beta cyclodextrin (SBECD), which has been reported to pose a risk of nephrotoxicity, thereby limiting its use in patients with renal dysfunction.

Isavuconazole (ISCZ) is an antifungal drug that does not contain SBECD and can be used by patients with renal dysfunction. However, there are few reports on the successful treatment of T. asahii fungemia in clinical settings.

We report a case of T. asahii fungemia with prominent renal dysfunction and absorption disorder and intestinal absorption disorder that was successfully treated with ISCZ.